Gregory L. Weaver
Gregory L. Weaver's purchase track record
How the stock did after each of Gregory L. Weaver's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/1/2026 | ALT | $31K | +1.0% | -8.3% | +16.4% |
| 3/6/2026 | ALT | $18K | -23.4% | -3.4% | +14.5% |
| 3/13/2025 | ALT | $52K | +37.5% | -29.0% | +19.3% |
| 6/20/2023 | ATOS | $49K | -17.7% | -25.0% | +8.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Atossa Announces Stapled CVR Plan and Raises Price Target. Atossa Therapeutics has unveiled a plan to issue a stapled convertible voting rights (CVR) linked to potential rare pediatric disease priority review voucher proceeds. The company also intends to allow shareholders to hold a stake in those proceeds. Ascendiant Capital lifted its price target to $25, and CEO Dr. Steven Quay will speak on clinical trials at ARDD 2026.
Transaction History
| ALT | ▲ Buy | Grant | 1,753 | $4K | 7/31/2026 | View on chart |
| ALT | ▲ Buy | Open Market | 10,000 | $31K | 4/1/2026 | View on chart |
| ALT | ▲ Buy | Open Market | 5,000 | $18K | 3/6/2026 | View on chart |
| ALT | ▲ Buy | Option Exercise | 18,750 | $0 | 11/11/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 5,672 | $24K | 11/11/2025 | View on chart |
| ALT | ▲ Buy | Open Market | 10,000 | $52K | 3/13/2025 | View on chart |
| ATOS | ▼ Sell | Open Market | 50,000 | $33K | 11/15/2023 | View on chart |
| ATOS | ▲ Buy | Open Market | 50,000 | $49K | 6/20/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Altimmune to attend Wells Fargo healthcare conference
Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.
Altimmune to attend Wells Fargo healthcare conference. Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.